Netflix, ZS Pharma Get Price Target Hikes; Gap Is Losing Relevance

In Friday's Analysts' Actions, we highlight higher price targets on Netflix Inc (NFLX) and ZS Pharma (ZSPH), while Gap Inc (GPS) gets hit with some negative notes.
Author:
Publish date:

In Friday's Analysts' Actions, we highlight higher price targets on Internet video streaming service Netflix Inc (NFLX) and biopharmaceutical company ZS Pharma (ZSPH), while global apparel retailer Gap Inc (GPS) gets hit with some negative notes. Netflix had its price target increased to $700 from $600 by analysts at RBC Capital, following the outcome of the research firm's surveys. Through the research in France and Germany, the surveys showed early traction in Europe. The firm maintained its OUTPERFROM rating on shares of Netflix. In the biotech sector, analysts at JPMorgan Chase raised its price target for shares of ZS Pharma to $75 from $57, following the stock's 45% gain this month in April. The firm maintained its OVERWEIGHT rating on the name, but said it believes treating high-blood potassium represents a multi-billion dollar opportunity just in the U.S. alone. And finally, Gap gets some negative notes following its disappointing first quarter earnings results, released late Thursday. Three firms issued negative notes, warning investors to 'stay on the sidelines.' Analysts at Cantor Fitzgerald lowered its price target to $42 from $44, while maintaining its HOLD rating. The firm doesn't see the Gap brand getting back on track anytime soon. TheStreet's Kurumi Fukushima reports in New York.